FDA Approves Besivance For The Treatment Of Bacterial Conjunctivitis
FDA approves Besivance for the treatment of bacterial conjunctivitis
The U.S. Food and Drug Administration (FDA) today approved the use of Besivance (0.6% besifloxacin suspension) for the treatment of bacterial conjunctivitis (non-viral), a form of ocular inflammatory and mucocutaneous secretions that increases For the characteristics of infectious eye disease.
Wiley A. Chambers, MD, a drug evaluation and research scientist at the FDA Department of Infectious Opal Products, said: "Bacterial conjunctivitis is a common disease that can infect every person of all ages and is available for healthcare professionals and patients Multiple treatment options are important because an effective drug treatment reduces the duration of the disease and reduces the chance of infection. "Bacterial conjunctivitis occurs in children, but it can occur in people of any age. Symptoms include bright red conjunctival congestion, swelling, adhesion of the eyelids, itching, mucopurulent or purulent discharges. Its duration is generally 7-14 days.
Clinical trials showed that the rate of regression of inflammation in patients who used the potion was faster than in the control group. This eye drop has proven to be suitable for one year old and above.
Less than 3% of patients in the clinical trial showed adverse reactions. These adverse reactions include redness, blurred vision, eye pain, inflammation and itching, and headaches. Besivance is just a topical solution, contraindication intraocular injection.